百纳千成 reported revenue of ¥0.56B for the period ended 2026-06-30, +313.6% year on year. Net income was ¥-0.01B, a -1.3% net margin on a 15.1% gross margin.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.56B | +313.6% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.01B | — |
| Gross margin | 15.1% | Net margin -1.3% |
| Revenue Q/Q | -88.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.48B | 84.9% |
| SG&A | ¥0.08B | 14.9% |
| Tax & other | ¥-0.01B | -1.5% |
| Item | Amount |
|---|---|
| Total assets | ¥2.99B |
| Total liabilities | ¥1.12B |
| Shareholders' equity | ¥1.87B |
| Equity / assets | 62.5% |
| Operating cash flow | ¥0.05B |
| Cash conversion (OCF / net income) | 519% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
吴通控股 ・ 蓝英装备 ・ 博雅生物 ・ *ST三六五 ・ 利亚德 ・ 三诺生物 ・ 富春股份 ・ 海峡创新 ・ ST长方 ・ 同有科技 ・ 聚飞光电 ・ 云意电气
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies